Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants

BACKGROUND: Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infection and hospitalization in infants. CONCLUSIONS: A single injection of nirsevimab administered before the RSV season protected healthy late-preterm and term infants from medically attended RSV-associated lower respiratory tract infection.

⚡ This is an original paraphrased summary — not copied from the abstract. Full paper available at the source link below.

• 1 Nirsevimab is a monoclonal antibody to the RSV fusion protein that has an extended half-life.
• 2 The efficacy and safety of nirsevimab in healthy late-preterm and term infants are uncertain.
• 3 METHODS: We randomly assigned, in a 2:1 ratio, infants who had been born at a gestational age of at least 35 weeks to receive a single intramuscular injection of nirsevimab or placebo before the start of an RSV season.

Understanding this could lead to better treatments, improved diagnostics, or a deeper grasp of how the human body works — benefiting patient care globally.

This summary is based on publicly available metadata and abstract. For the full research paper, visit the original source: